<form id="lwufo"><acronym id="lwufo"></acronym></form>
          Log in
          E-mail
          Password
          Remember
          Forgot password ?
          Become a member for free
          Sign up
          Sign up
          New member
          Sign up for FREE
          New customer
          Discover our services
          Settings
          Settings
          Dynamic quotes 
          OFFON

          MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

          JOHNSON & JOHNSON

          (JNJ)
            Report
           SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
          Quotes 5-day view   Delayed Quote. Delayed Nyse
          07/20/2020 07/21/2020 07/22/2020 07/23/2020 07/24/2020 Date
          149.6(c) 149.74(c) 150.01(c) 149.61(c) 148.12(c) Last
          6 191 457 5 579 687 5 910 193 6 566 269 5 339 528 Volume
          +0.17% +0.09% +0.18% -0.27% -1.00% Change
          More quotes
          Financials (USD)
          Sales 2020 80 530 M - -
          Net income 2020 17 416 M - -
          Net Debt 2020 3 827 M - -
          P/E ratio 2020 22,9x
          Yield 2020 2,69%
          Sales 2021 87 370 M - -
          Net income 2021 21 995 M - -
          Net cash position 2021 5 255 M - -
          P/E ratio 2021 18,2x
          Yield 2021 2,82%
          Capitalization 394 B 394 B -
          EV / Sales 2020 4,94x
          EV / Sales 2021 4,45x
          Nbr of Employees 132 200
          Free-Float 84,3%
          More Financials
          Company
          Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (51.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (31.6%): diagnostic systems,... 
          Sector
          Pharmaceuticals
          Calendar
          10/13 | 06:45amEarnings Release
          More about the company
          Surperformance© ratings of Johnson & Johnson
          Trading Rating : Investor Rating :
          More Ratings
          Latest news on JOHNSON & JOHNSON
          04:07pJOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
          AQ
          09:52aJOHNSON & JOHNSON : Janssen Gets CHMP Positive Opinion for Expanded Use of Imbru..
          DJ
          07:15aJOHNSON & JOHNSON : Aleafia Health Approved by Janssen Pharmaceuticals to Admini..
          AQ
          07/22EXCLUSIVE : Novavax executives could get big payday even if vaccine fails
          RE
          07/21Pharma Companies Split on Coronavirus Vaccine Pricing Plans
          DJ
          07/21JOHNSON & JOHNSON : On Pace for Longest Winning Streak Since June 2019 -- Data T..
          DJ
          07/21WATCH LIVE : Pharma execs testify in Congress on COVID-19 vaccine
          AQ
          07/21SANUWAVE's Acquisition Of Celularity's UltraMIST?Ultrasound Hearing Therapy ..
          AQ
          07/21KARO PHARMA PUBL : Second-quarter report 2020
          AQ
          07/20JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2020
          PR
          07/20JOHNSON & JOHNSON : - Interim Six-Month Data of RPGR Gene Therapy Shows Signific..
          AQ
          07/20JOHNSON & JOHNSON : The Janssen Pharmaceutical Companies - Interim Six-Month Dat..
          AQ
          07/20JOHNSON & JOHNSON : to Participate in Citi 'Of Hearts and Minds' Conference Call..
          AQ
          07/17JOHNSON & JOHNSON : to Participate in Citi ‘Of Hearts and Minds' Conferenc..
          PU
          07/17JOHNSON & JOHNSON : Interim Six-Month Data of RPGR Gene Therapy Shows Significan..
          PU
          More news
          News in other languages on JOHNSON & JOHNSON
          04:07pJOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
          09:52aJOHNSON & JOHNSON : Janssen Gets CHMP Positive Opinion for Expanded Use of Imbru..
          07:15aJOHNSON & JOHNSON : Aleafia Health Approved by Janssen Pharmaceuticals to Admini..
          07/22EXCLUSIVE : Novavax executives could get big payday even if vaccine fails
          07/21Pharma Companies Split on Coronavirus Vaccine Pricing Plans
          More news
          Chart JOHNSON & JOHNSON
          Duration : Period :
          Johnson & Johnson Technical Analysis Chart | MarketScreener
          Full-screen chart
          Technical analysis trends JOHNSON & JOHNSON
          Short TermMid-TermLong Term
          TrendsBullishBullishBullish
          Income Statement Evolution
          Consensus
          Sell
          Buy
          Mean consensus OUTPERFORM
          Number of Analysts 22
          Average target price 163,53 $
          Last Close Price 149,61 $
          Spread / Highest target 21,6%
          Spread / Average Target 9,30%
          Spread / Lowest Target -5,75%
          EPS Revisions
          Managers
          NameTitle
          Alex Gorsky Chairman & Chief Executive Officer
          Joseph J. Wolk Chief Financial Officer & Executive Vice President
          Paulus Stoffels Chief Scientific Officer
          James D. Swanson Global Chief Information Officer & Executive VP
          Charles O. Prince Independent Director
          Sector and Competitors
          1st jan.Capitalization (M$)
          JOHNSON & JOHNSON2.56%394 162
          ROCHE HOLDING AG4.49%301 237
          PFIZER, INC.-1.58%213 361
          MERCK & CO., INC.-14.17%197 031
          NOVARTIS AG-13.22%189 652
          ABBVIE INC.10.72%172 762
          官方真人棋牌游戏平台